Back to Journals » Research and Reports in Urology » Volume 4

Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder

Authors Wagg A

Received 19 September 2012

Accepted for publication 22 October 2012

Published 27 November 2012 Volume 2012:4 Pages 57—64

DOI https://doi.org/10.2147/RRU.S28943

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Adrian Wagg

Department of Medicine, University of Alberta, Edmonton, Alberta, Canada

Abstract: Oxybutynin is an efficacious treatment for overactive bladder, but its clinical utility is hampered by relative intolerability due to its side effect profile. Over the last few years, various attempts to enhance the tolerability of oxybutynin by varying the drug delivery mechanism have been introduced and have included extended release, rectal suppository, transdermal patch, and gel formulations. The recent introduction of a transdermal oxybutynin gel in a sachet form has been complemented by the administration of gel in a metered dose pump. This paper reviews the available evidence for transdermal oxybutynin gel and, where it exists, for the pump-based gel. The clinical utility of the pump-based gel is discussed.

Keywords: urgency incontinence, overactive bladder, oxybutynin, transdermal

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]